Rapid Insight Login

News

    Acumetis Launches as a Single Integrated Brand to Transform Life Sciences Commercialization

    Leading Pharmaceutical and Biotech Consultancies Combine to Create a Full-Service Commercialization Powerhouse

    See the Press Release

    Expertise

    Launch Excellence

    From strategy development and tactical planning to seamless execution, we help to de-risk and accelerate your launch.

    Specialty data, insights, and analytics

    Rare Disease Insights & Analytics

    We deliver granular specialty market understanding not available elsewhere, that delivers insights and drives strategy to unlock brand performance.

    Medical Affairs

    With a focus on insights, strategy, and medical communications, we partner with clients to unlock the potential for new therapies or drive forward into new therapeutic areas.

    Patient Services

    We go beyond research, leveraging innovations like AI to create breakthrough patient experience programs that remove barriers to treatment, and drive adherence.

    Market Access & HEOR

    We collaborate with clients to gather insights, craft strategies, and execute plans that create value, gain patient access, and improve the patient experience.

    Commercial Strategy

    Experienced commercial leaders, with proven success, pressure-test assumptions, connect brand ambition to business reality, and deliver executable strategies leadership teams can stand behind.

    Thought Leadership

    Patient Access for dtp models

    Why Direct-to-Patient Is Not One-Size-Fits-All

    Explore scalable direct-to-patient (DTP) models that improve affordability, time-to-therapy, and patient engagement with a strategic, data-driven approach. Read here.
    Herspiegel policy changes and strategic planning

    What the National Cancer Plan for England Signals for Oncology Innovation and Access

    Explore how the National Cancer Plan for England is reshaping oncology access expectations, regulatory timelines, and HTA and JCA planning. Read here.
    Herspiegel policy changes and strategic planning

    What Is the EU’s Pharmaceutical Legislation Agreement Telling the Industry

    Overview of the EU pharmaceutical legislation agreement and its implications for the industry, from market exclusivity to regulatory reform. Read here.
    Herspiegel Stock Image Patient Ordering Medcation

    The “Direct” Continuum: Decoding Direct-to-Patient and Direct-to-Employer for Commercial Success

    Discover the evolution of direct-to-patient distribution models, which modernize patient access, affordability, and engagement. Read here.
    Herspiegel Rare Disease Commercial Conversations

    Rare Disease Launch: Best Practices – Planning, Budget & Timing

    The video outlines best planning, timing, and budgeting practices in rare disease product launches. Watch here.
    Most Favored Nation prescription drug price policy brief

    Most Favored Nation: From Policy Concept to Political Imperative

    President Trump’s July 31st letter creates a rising imperative that cannot be ignored. Learn more about the notable escalations and expansions.

    Case Studies

    How Go/No-Go Assessment Supports Strategic Decision-Making

    Learn how Go/No-Go assessments evaluate market access, pricing, and value drivers to guide strategic decisions for pipeline products. Read here.
    See the Case Study
    Market Access Assessment

    How PICOS Prediction Supports JCA Strategy and Submission

    Learn how PICOS prediction guides JCA evidence alignment, supports multi-market HTA planning, and strengthens submission strategy. Read here.
    See the Case Study

    How Market Access Strategy Supports Launch Success in the Middle East

    Learn how model adaptation, HTA mapping, affiliate engagement, and launch sequencing drive successful market access in the Middle East. Read here.
    See the Case Study
    Market Access Strategy

    Let's Talk

    New Contact Form Home

    Let's Talk Home page

    "*" indicates required fields